Structure Therapeutics Inc.

Clinical-stage metabolic biotech developing oral small-molecule GPCR agonists, led by aleniglipron for obesity.

Back to company catalog

Obesity & metabolic disease · Structure-based oral small-molecule GPCR agonists · Phase 2 complete / Phase 3 planned Q3 2026

Compare report options